Overview of Current Notices
For additional Relevant links with regards to Content Development Information please click here Content Development Information
Planned Release date
(*this is provisional only and is subject to change)
|1||LOINC timeline changes - please refer to Roadmap link here LOINC||July 2018 and potentially other future releases.|
Revision of IS A relationships for anatomy concepts
The new anatomy concept model has implemented the new Description Logic features, e.g. reflective and transitive property, general concept axioms, for consistent logical modeling. However, the new model cannot be implemented in production because these DL features currently are not available in production. The implementation of them will depend on the enhanced logic profile for SNOMED CT which is under development by the Modeling AG. Yet, the inferred IS A relationship from the OWL anatomy ontology can be reviewed and implemented in the production. This will utilise the outcomes of the new anatomy model as well as evaluate the design of the new model. In particular, it is important to review the changes of IS-A relationships in anatomy for quality assurance and minimise impact to other hierarchies, such as disorders, procedures, observables, situations etc.
The first subject area for revision is the sub-hierarchy of skin structure. The majority changes have been made in the January 2018 release. The rest will be completed in July 2018 release.
For July 2018 release, the subject area for revision of IS A relationships will be determined and updated in the following confluence page.
|July 2018 International Edition|
Summary of Drugs changes
New hierarchies 766940004 | Role (role) and subhierarchy 766941000 | Therapeutic role (role) created with additional subtypes to be added in future releases
New semantic tags (role)
Attribute types New attributes created:
Grouper concepts representing disposition, intended site, and/or structure Grouper concepts representing disposition, intended site, and/or structure sufficiently defined by modeling to proximal primitive concept, adding defining attributes, and updating descriptions per editorial guidelines (n≈550).
New high level grouper concepts created as an incremental improvement with additional subtypes to be added in future releases:
Product role concepts Concepts representing product role relocated as stated descendants of 763087004 | Medicinal product categorized by role (product) with definition status = primitive and attributes inactivated (n≈ 400)
For further details see Briefing Note Use of Additional Axiom Functionality and Remodeling Product Roles
Medicinal product (MP) concepts - MP-containing concepts sufficiently defined by modeling to proximal primitive concept, adding defining attributes, and updating descriptions per editorial guidelines (n≈ 3750). Includes the following attributes:
Medicinal product form (MPF) concepts - MPF-containing concepts sufficiently defined by modeling to proximal primitive concept, adding defining attributes, and updating descriptions per editorial guidelines (n≈2100). Includes the following attributes:
Clinical drug (CD) concepts - CD-containing precisely concepts sufficiently defined by modeling to proximal primitive concept, adding defining attributes, and updating descriptions per editorial guidelines (n≈ 4850). Includes the following attributes:
Documentation Notification for Briefing Notes, Editorial Guidelines, and other documentation updates are posted on the project group website as they become available; see Drug Model Working Group - Directory for details
|July 2018 International Edition|
|4||Summary of Substances Changes|
Substance groupers including Disposition, Structure and Combined groupers have been remodelled and additional grouper concepts created as required. The inactivation of role groupers in the substances hierarchy has been initiated.
Role groupers within the substances hierarchy are being inactivated where this is possible without creating disruption in other hierarchies. At the start of this work there were approximately 600 role groupers. Currently in the region of 100 role grouper substance concepts have been inactivated or remodelled.This work is ongoing.
Many of these role grouper concepts remain in the substances hierarchy pending a solution for the roles concepts within the terminology as a whole and so will still be present in the July 2018 release.
Structural groupers within the substance hierarchy have been modelled as primitive concepts.
Existing structural grouper concepts in the substances hierarchy have been retained where appropriate and have been remodelled to conform to SCT Editorial policy.
New structural grouper concepts have been added.
Groupers that identify X or derivatives where X is a specific substance will be inactivated. Some of these concepts have already been inactivated. As the implementation of the IS Modification attibute is carried out the remainder of these concepts will be inactivated.
Structural groupers that reference a chemical group will be retained.
e.g. Amides and derivatives (substance)
Where the structural group name also refers to a specific chemical the grouper has been re-termed “Substance with X structure”
e.g. Substance with tetracycline structure (substance)
Combined groupers that include a role will be inactivated where this is possible without causing disruption in other hierarchies. Inactivation of some of these concepts in the substances hierarchy is waiting on a solution for the roles concepts within the terminology as a whole and so will still be present in the July 2018 release.
Groupers of disposition + structure will be retained in the substance hierarchy. Existing concepts have been remodelled to conform to SCT Editorial policy. Examples as below.
Antimony compound with antiprotozoal mechanism of action (substance)
Quaternary ammonium compound with anticholinergic mechanism of action (substance)
Piperidine derivative with histamine receptor antagonist mechanism of action (substance)
New concepts will be added as required.
Use of the Is Modification attribute
To date, we have added n≈1200 new S Modification attribute. This number will most likely increase by the end of the release. This has achieved a flattening of the substance hierarchy. Priority has been given to the remodelling of substances associated with the definition of medicinal products.
The following guidelines have been developed.
1. Substances may have zero to many Is modification attribute(s). e.g Iodine (131-I) labelled monoclonal antibody (substance) has 2 IS MODIFICATION attribute values.
2. Salts have a IS MODIFICATION relationship to the base e.g. Doxepin hydrochloride (substance) IS MODIFICATION of Doxepin (substance)
3. Hydrates have a IS MODIFICATION relationship to the unspecified salt e.g. Caffeine hydrate (substance) IS MODIFICATION of Caffeine (substance)
4. Anhydrous salts have a IS MODIFICATION relationship to the unspecified salt e.g. Theophylline anhydrous (substance) IS MODIFICATION of Theophylline (substance)
5. Stereoisomers are subtypes of the unspecified substance. e.g.. Dextrothyroxine IS A thyroxine.
6. There is no IS MODIFICATION relationship between stereoisomers.
Further guidelines will be added to the published documentation as they are developed.
The initial population of the IS MODIFICATION attribute is still subject to manual authoring input to ensure compliance to Editorial guidelines and so some areas of content may appear to be non-conformant in the Alpha release data.
|July 2018 International Edition|
Test and procedure status: Inactivated 143 concepts in the Situations and Findings hierarchies with pattern "Test/procedure OFFERED" and "Test/procedure NOT OFFERED" as these represent an administrative status.
Inactivation of Agencies and organizations (qualifier value) and subtypes: moved to UK extension i.e. 66 concepts inactivated.